Research recommendations coming out of this guidance Strategies to slow the progression of age-related macular degeneration (AMD):- What is the effectiveness of antioxidant and zinc supplements on AMD disease progression for people with early AMD at high risk of progression in the context of a randomised controlled trial? Organisational models for AMD diagnosis and management:- What is the long-term effectiveness, in terms of patient-relevant outcomes including visual acuityand quality of life, of different models of care that aim to reduce time from initial presentation to referral, diagnosis and treatment? Stopping rules for antiangiogenic treatment for late AMD (wet):- When should anti-vascular endothelial growth factor (VEGF) treatment be suspended or stoppedin people with late AMD (wet)? Frequency of monitoring:- What is the long-term cost effectiveness, in terms of patient-relevant outcomes including bestcorrected visual acuity and quality of life, of different review frequencies/strategies for people at risk of progression to late AMD (wet active)? Self-monitoring strategies:- Does earlier detection of the incidence of late AMD (wet active) by self-monitoring in people diagnosed with early AMD, indeterminate AMD or late AMD (dry) lead to earlier treatment and better long-term outcomes?
Strategies to slow the progression of age-related macular degeneration (AMD):- What is the effectiveness of antioxidant and zinc supplements on AMD disease progression for people with early AMD at high risk of progression in the context of a randomised controlled trial?
Organisational models for AMD diagnosis and management:- What is the long-term effectiveness, in terms of patient-relevant outcomes including visual acuityand quality of life, of different models of care that aim to reduce time from initial presentation to referral, diagnosis and treatment?
Stopping rules for antiangiogenic treatment for late AMD (wet):- When should anti-vascular endothelial growth factor (VEGF) treatment be suspended or stoppedin people with late AMD (wet)?
Frequency of monitoring:- What is the long-term cost effectiveness, in terms of patient-relevant outcomes including bestcorrected visual acuity and quality of life, of different review frequencies/strategies for people at risk of progression to late AMD (wet active)?
Self-monitoring strategies:- Does earlier detection of the incidence of late AMD (wet active) by self-monitoring in people diagnosed with early AMD, indeterminate AMD or late AMD (dry) lead to earlier treatment and better long-term outcomes?